Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This thesis explores both environmental and genetic factors in prostate cancer, focusing on surrogate hormone markers, medical radiation, family history, and genetic polymorphisms related to DNA repair and hormone marker genes, but reports no new clinical findings.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This overview highlights the exploration of mesenchymal stromal cells as potential treatments for COVID-19, noting their regenerative and immunomodulatory properties for reducing ARDS severity in critically ill patients, but it provides no new clinical results.

This abstract discusses the transformative impact of digital technologies like 3D scanning and intraoral imaging in dentistry, emphasizing their role in enhancing implant placement precision and root canal treatments, which can improve treatment processes and patient outcomes.

This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study found that 5% primed conditioned medium from human umbilical cord blood-derived mesenchymal stromal cells significantly improved hair density, thickness, and growth rate in patients with androgenetic alopecia.

This study found that vitamin D regulates cholesterol metabolism and may influence prostate cancer development through mechanisms affecting prostate cell growth and sex hormone metabolism.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

This study found that men with a cutaneous melanoma diagnosis had an increased risk of subsequently being diagnosed with prostate cancer compared to those without melanoma.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This study found that finasteride significantly reduced VEGF expression and microvessel density in prostatic suburethral tissue, suggesting a mechanism for decreased bleeding in patients with benign prostatic hyperplasia.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This review discusses the potential of plant polyphenols to overcome multidrug resistance in various solid cancers and reports no new experimental results; further research is suggested.

In a testosterone-induced BPH rat model, this study found that ursolic acid treatment significantly reduced prostate weight and hormone levels, suggesting it may inhibit BPH development.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.

This case report suggests that oral finasteride, used for benign prostatic hyperplasia, may be associated with intraoperative floppy-iris syndrome during cataract surgery.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This study found that olive leaves extract significantly decreased prostate index, serum PSA, testosterone, and DHT levels in male rats with testosterone-induced benign prostatic hyperplasia, and showed potential as a therapeutic option due to its positive effects on prostate histology and antioxidant activity.

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.

This study found that Tripterygium wilfordii multiglycoside significantly inhibited testosterone-induced benign prostatic hyperplasia in rats without causing toxicity, suggesting its potential as a therapy for BPH.